Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Accured Expenses: 2020-2025

Historic Change in Accured Expenses for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $4.6 million.

  • Xeris Biopharma Holdings' Change in Accured Expenses rose 884.65% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 67.57%. This contributed to the annual value of $3.6 million for FY2024, which is 162.34% up from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Change in Accured Expenses stood at $4.6 million for Q3 2025, which was down 13.70% from $5.4 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' Change in Accured Expenses' 5-year high stood at $7.9 million during Q4 2021, with a 5-year trough of -$13.9 million in Q1 2023.
  • For the 3-year period, Xeris Biopharma Holdings' Change in Accured Expenses averaged around -$74,273, with its median value being $1.4 million (2024).
  • Over the last 5 years, Xeris Biopharma Holdings' Change in Accured Expenses had its largest YoY gain of 884.65% in 2025, and its largest YoY loss of 664.11% in 2025.
  • Xeris Biopharma Holdings' Change in Accured Expenses (Quarterly) stood at $7.9 million in 2021, then slumped by 90.50% to $751,000 in 2022, then soared by 718.91% to $6.2 million in 2023, then plummeted by 78.02% to $1.4 million in 2024, then skyrocketed by 884.65% to $4.6 million in 2025.
  • Its Change in Accured Expenses stands at $4.6 million for Q3 2025, versus $5.4 million for Q2 2025 and -$8.6 million for Q1 2025.